Company Overview and News

1
Gifts That Keep On Giving: Is Backdating Back? : TheCorporateCounsel.net Blog

2018-01-03 thecorporatecounsel.net
Last month, the WSJ published an investigative report that suggested that hundreds of corporate insiders frequently had uncanny timing when it came to gifts of company stock.

 
Unilife EX-99.2

2017-10-31 sec.gov
EX-99.2 Exhibit 99.2 UNITED STATES BANKRUPTCY COURT DISTRICT OF DELAWARE   In re Unilife Corporation, et al. [1]       Case No. 17-10805       Reporting Period: Sept. 1 to Sept. 30, 2017 MONTHLY OPERATING REPORT File with Court and submit copy to United States Trustee within 20 days after end of month Submit copy of report to any official committee appointed in the case.               Document      Affidavit/Supplement          REQUIRED DOCUMENTS    Form No.

 
Unilife EX-99.1

2017-10-31 sec.gov
EX-99.1 Exhibit 99.1 UNITED STATES BANKRUPTCY COURT DISTRICT OF DELAWARE   In re Unilife Corporation, et al. [1]      Case No. 17-10805      Reporting Period: Aug. 1 to Aug. 31, 2017 MONTHLY OPERATING REPORT File with Court and submit copy to United States Trustee within 20 days after end of month Submit copy of report to any official committee appointed in the case.   REQUIRED DOCUMENTS    Form No.

 
Unilife FORM 8-K (Current Report/Significant Event)

2017-10-31 sec.gov
Form 8-K     UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 19, 2017     UNILIFE CORPORATION (Exact name of Registrant as Specified in Charter)       Delaware   001-34540   27-1049354 (State or Other Jurisdiction of Incorporation)   (Commission File Number)   (IRS Employer Identification No.

 
Unilife XBRL TAXONOMY EXTENSION SCHEMA

2017-10-05 sec.gov
101 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 103 - Statement - Consolidated Balance Sheets link:calculationLink link:presentationLink link:definitionLink 104 - Statement - Consolidated Balance Sheets (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 105 - Statement - Consolidated Statements of Operations and Comprehensive Loss link:calculationLink link:presentationLink link:definitionLink 106 - Statem

 
Unilife EX-32.2

2017-10-05 sec.gov
EX-32.2 Exhibit 32.2 Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the quarterly report of Unilife Corporation (the “Company”) on Form 10-Q for the quarterly period ended December 31, 2013 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, R.

 
Unilife EX-32.1

2017-10-05 sec.gov
EX-32.1 Exhibit 32.1 Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the quarterly report of Unilife Corporation (the “Company”) on Form 10-Q for the quarterly period ended December 31, 2013 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Alan Shortall, Chief Executive Officer of the Company, certify, pursuant to 18 U.

 
Unilife EX-31.2

2017-10-05 sec.gov
EX-31.2 Exhibit 31.2 Certification of Chief Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, R. Richard Wieland II, certify that:   1. I have reviewed this quarterly report on Form 10-Q of Unilife Corporation;   2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of t

 
Unilife EX-31.1

2017-10-05 sec.gov
EX-31.1 Exhibit 31.1 Certification of Chief Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Alan Shortall, certify that:   1. I have reviewed this quarterly report on Form 10-Q of Unilife Corporation;   2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circu

 
Unilife EX-15

2017-10-05 sec.gov
EX-15 Exhibit 15 Awareness Letter from Independent Registered Public Accounting Firm February 10, 2014 Unilife Corporation York, Pennsylvania Re: Registration Statements No. 333-173195, 333-164964, 333-178882, 333-186049 and 333-193358 With respect to the subject registration statements, we acknowledge our awareness of the use therein of our report dated February 10, 2014 related to our review of interim financial information.

 
Unilife FORM 10-Q (Quarterly Report)

2017-10-05 sec.gov
Form 10-Q Table of Contents     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 10-Q     (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2013 OR   ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from                      to                      Commission file number 001-34540     UNILIFE CORPORATION

 
Unilife ER

2017-10-04 sec.gov
March 12, 2015 Via E-mail Alan Shortall Chief Executive Officer Unilife Corporation 250 Cross Farm Lane York, Pennsylvania 17406 Re: Unilife Corporation Form 10-K for the Fiscal Year Ended June 30, 2014 Response dated February 27, 2015 File No. 1-34540 Dear Mr. Shortall: We have reviewed your February 27, 2015 response to our comment letter and have the following comment.

 
Unilife ESP

2017-10-04 sec.gov
Correspondence April 9, 2015 Via EDGAR (Correspondence) U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Mr. Martin James, Senior Assistant Chief Accountant     Re: Unilife Corporation Form 10-K for the Fiscal Year Ended June 30, 2014 Response dated February 27, 2015 File No. 001-34540 Dear Mr. James: This letter is being submitted in response to the written comments of the staff (the “Staff”) of the United States Securi

 
Unilife ER

2017-10-04 sec.gov
April 10, 2015 Via E-Mail Alan Shortall Chief Executive Officer Unilife Corporation 250 Cross Farm Lane York, Pennsylvania 17406 Re: Unilife Corporation Form 10-K for the Fiscal Year Ended June 30, 2014 Filed September 15, 2014 File No. 1-34540 Dear Mr. Shortall: We have completed our review of your filings. We remind you that our comments or changes to disclosure in response to our comments do not foreclose the Commission from taking any action with respect

 
Unilife PRE 14A

2017-10-04 sec.gov
PRE 14A     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant  þ                            Filed by a Party other than the Registrant  ¨ Check the appropriate box:   þ   Preliminary Proxy Statement ¨   Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

12h - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

12h - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

22h - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...